- Home
- BXP vs IONS Comparison
BXP vs IONS Comparison
Compare BXP & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXP | IONS |
|---|---|---|
| Founded | 1970 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 12.9B |
| IPO Year | 1997 | 1991 |
Fundamental Metrics
Financial Performance| Metric | BXP | IONS |
|---|---|---|
| Price | $67.56 | $80.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 22 |
| Target Price | $77.33 | ★ $83.64 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 01-27-2026 | 02-18-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,425,025,000.00 | $966,957,000.00 |
| Revenue This Year | $3.30 | $29.72 |
| Revenue Next Year | $1.58 | $0.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.42 | ★ 20.41 |
| 52 Week Low | $54.22 | $23.95 |
| 52 Week High | $79.33 | $86.15 |
Technical Indicators
Market Signals| Indicator | BXP | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 54.72 |
| Support Level | $68.55 | $76.08 |
| Resistance Level | $68.91 | $86.15 |
| Average True Range (ATR) | 1.24 | 2.19 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 39.48 | 46.74 |
Price Performance
Historical ComparisonAbout BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.